, Volume 42, Issue 2, pp 263–279 | Cite as

An Italian consensus for invasive candidiasis management (ITALIC)

  • L. ScudellerEmail author
  • C. Viscoli
  • F. Menichetti
  • V. del Bono
  • F. Cristini
  • C. Tascini
  • M. Bassetti
  • P. Viale



Invasive candidiasis (IC) has primarily been studied in intensive care unit (ICU) patients, although, in reality, a vast majority of these infections occur outside of the ICU. The recent publication of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines also deal with the non-ICU population, but many uncertainties remain on the management of IC, particularly in non-critically ill patients.


The Italian Society of Antimicrobial Therapy, Società Italiana di Terapia Antimicrobica (SITA), produced practical, hospital-wide recommendations on the management of Candida infection in non-immunocompromised patients in the hospital ward.

Results and discussion

Our focus is on patient stratification in terms of risk factors for IC and of clinical severity, emphasising a high index of suspicion to ensure early diagnosis, early treatment and de-escalation when a patient is clinically stable, in order to optimise resource allocation.


Invasive candidiasis Diagnosis Management Risk stratification Clinical severity Review Consensus Recommendations 



We thank Federico Pea and Maurizio Sanguinetti for their important contributions to the discussion of the recommendations.

Conflict of interest

This work, including travel and meeting expenses, was funded by an unrestricted grant by MSD Italia Srl. The sponsor had no role in selecting the participants, reviewing the literature, defining recommendations, drafting or reviewing the paper, or in the decision to submit the manuscript for publication. All views expressed are solely those of the authors. All authors have completed the International Committee of Medical Journal Editors (ICMJE) form, which is available upon request.


  1. 1.
    Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54:1739–46. doi: 10.1093/cid/cis305.PubMedGoogle Scholar
  2. 2.
    Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One. 2011;6:e24198. doi: 10.1371/journal.pone.0024198.PubMedCentralPubMedGoogle Scholar
  3. 3.
    Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol. 1998;36:1886–9.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis. 1997;24:584–602.PubMedGoogle Scholar
  5. 5.
    Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29:239–44. doi: 10.1086/520192.PubMedGoogle Scholar
  6. 6.
    Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996;100:617–23 (pii:S0002934395000100).PubMedGoogle Scholar
  7. 7.
    Rocco TR, Reinert SE, Simms HH. Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg. 2000;135:160–5.PubMedGoogle Scholar
  8. 8.
    Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006;6:21. doi: 10.1186/1471-2334-6-21.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–5. doi: 10.1128/AAC.49.9.3640-3645.2005.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25–31. doi: 10.1086/504810.PubMedGoogle Scholar
  11. 11.
    Hsu DI, Nguyen M, Nguyen L, Law A, Wong-Beringer A. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J Antimicrob Chemother. 2010;65:1765–70. doi: 10.1093/jac/dkq216.PubMedGoogle Scholar
  12. 12.
    Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35. doi: 10.1086/596757.PubMedGoogle Scholar
  13. 13.
    Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2013;18:19–37. doi: 10.1111/1469-0691.12039.Google Scholar
  14. 14.
    Clancy CJ, Nguyen MH. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56:1284–1292. doi: 10.1093/cid/cit006.PubMedGoogle Scholar
  15. 15.
    Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS One. 2011;6:e20476. doi: 10.1371/journal.pone.0020476.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6. doi: 10.1136/bmj.39489.470347.AD.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336:995–8. doi: 10.1136/bmj.39490.551019.BE.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Jaeschke R, Guyatt GH, Dellinger P, Schünemann H, Levy MM, Kunz R, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ. 2008;337:a744.PubMedGoogle Scholar
  19. 19.
    Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106–10. doi: 10.1136/bmj.39500.677199.AE.PubMedCentralPubMedGoogle Scholar
  20. 20.
    Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. BMJ. 2008;336:1049–51. doi: 10.1136/bmj.39493.646875.AE.PubMedCentralPubMedGoogle Scholar
  21. 21.
    National Institute for Health and Clinical Excellence (NICE). The guidelines manual. Last updated January 2009.Google Scholar
  22. 22.
    Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55:532–8. doi: 10.1128/AAC.01128-10.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench MT, et al. Candida spp. with acquired echinocandin resistance, France, 2004–2010. Emerg Infect Dis. 2012;18:86–90. doi: 10.3201/eid1801.110556.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Viale P. Candida colonization and candiduria in critically ill patients in the intensive care unit. Drugs. 2009;69:51–7. doi: 10.2165/11315640-000000000-00000.PubMedGoogle Scholar
  25. 25.
    Ben-Ami R, Weinberger M, Orni-Wasserlauff R, Schwartz D, Itzhaki A, Lazarovitch T, et al. Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol. 2008;46:2222–6. doi: 10.1128/JCM.00214-08.PubMedCentralPubMedGoogle Scholar
  26. 26.
    American College of Chest Physicians/Society of Critical Care. Medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–74.Google Scholar
  27. 27.
    Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220:751–8.PubMedCentralPubMedGoogle Scholar
  28. 28.
    Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol. 2005;43:235–43.PubMedGoogle Scholar
  29. 29.
    Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis. 2007;26:271–6. doi: 10.1007/s10096-007-0270-z.PubMedGoogle Scholar
  30. 30.
    León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34:730–7. doi: 10.1097/01.CCM.0000202208.37364.7D.PubMedGoogle Scholar
  31. 31.
    León C, Ruiz-Santana S, Saavedra P, Galván B, Blanco A, Castro C, et al. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37:1624–33. doi: 10.1097/CCM.0b013e31819daa14.PubMedGoogle Scholar
  32. 32.
    Eggimann P, Ostrosky-Zeichner L. Early antifungal intervention strategies in ICU patients. Curr Opin Crit Care. 2010;16:465–9. doi: 10.1097/MCC.0b013e32833e0487.PubMedGoogle Scholar
  33. 33.
    Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi MA, Bello G, et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1 → 3)-beta-d-glucan assay, Candida score, and colonization index. Crit Care. 2011;15:R249. doi: 10.1186/cc10507.PubMedCentralPubMedGoogle Scholar
  34. 34.
    Ostrosky-Zeichner L, Pappas PG, Shoham S, Reboli A, Barron MA, Sims C, et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses. 2009;54:46–51. doi: 10.1111/j.1439-0507.2009.01756.x.Google Scholar
  35. 35.
    Playford EG, Lipman J, Sorrell TC. Prophylaxis, empirical and preemptive treatment of invasive candidiasis. Curr Opin Crit Care. 2010;16:470–4. doi: 10.1097/MCC.0b013e32833e10e8.PubMedGoogle Scholar
  36. 36.
    Hermsen ED, Zapapas MK, Maiefski M, Rupp ME, Freifeld AG, Kalil AC. Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case–control study. Crit Care. 2011;15:R198. doi: 10.1186/cc10366.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med. 2009;37:1612–8. doi: 10.1097/CCM.0b013e31819efac0.PubMedGoogle Scholar
  38. 38.
    Charles PE, Castro C, Ruiz-Santana S, León C, Saavedra P, Martín E. Serum procalcitonin levels in critically ill patients colonized with Candida spp.: new clues for the early recognition of invasive candidiasis? Intensive Care Med. 2009;35:2146–50. doi: 10.1007/s00134-009-1623-0.PubMedGoogle Scholar
  39. 39.
    Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis. 1993;17:103–9 (pii:0732-8893(93)90020-8).PubMedGoogle Scholar
  40. 40.
    Ellis M, Al-Ramadi B, Bernsen R, Kristensen J, Alizadeh H, Hedstrom U. Prospective evaluation of mannan and anti-mannan antibodies for diagnosis of invasive Candida infections in patients with neutropenic fever. J Med Microbiol. 2009;58:606–15. doi: 10.1099/jmm.0.006452-0.PubMedGoogle Scholar
  41. 41.
    Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care. 2010;14:R222. doi: 10.1186/cc9365.PubMedCentralPubMedGoogle Scholar
  42. 42.
    Tokunaga S, Ohkawa M, Takashima M. Diagnostic value of determination of serum mannan concentrations in patients with candiduria. Eur J Clin Microbiol Infect Dis. 1993;12:542–5.PubMedGoogle Scholar
  43. 43.
    Verduyn Lunel FM, Donnelly JP, van der Lee HA, Blijlevens NM, Verweij PE. Circulating Candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy. Clin Microbiol Infect. 2009;15:380–6. doi: 10.1111/j.1469-0691.2008.02654.x.PubMedGoogle Scholar
  44. 44.
    Arendrup MC, Bergmann OJ, Larsson L, Nielsen HV, Jarløv JO, Christensson B. Detection of candidaemia in patients with and without underlying haematological disease. Clin Microbiol Infect. 2009;16:855–62. doi: 10.1111/j.1469-0691.2009.02931.x.PubMedGoogle Scholar
  45. 45.
    Hsu JL, Ruoss SJ, Bower ND, Lin M, Holodniy M, Stevens DA. Diagnosing invasive fungal disease in critically ill patients. Crit Rev Microbiol. 2011;37:277–312. doi: 10.3109/1040841X.2011.581223.PubMedGoogle Scholar
  46. 46.
    Laín A, Elguezabal N, Moragues MD, García-Ruiz JC, del Palacio A, Pontón J. Contribution of serum biomarkers to the diagnosis of invasive candidiasis. Expert Rev Mol Diagn. 2008;8:315–25. doi: 10.1586/14737159.8.3.315.PubMedGoogle Scholar
  47. 47.
    Preuner S, Lion T. Towards molecular diagnostics of invasive fungal infections. Expert Rev Mol Diagn. 2009;9:397–401. doi: 10.1586/erm.09.27.PubMedGoogle Scholar
  48. 48.
    Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1 → 3)-beta-d-glucan assay for the diagnosis of invasive fungal infections—a study based on autopsy cases from 6 years. Clin Infect Dis. 2008;46:1864–70. doi: 10.1086/588295.PubMedGoogle Scholar
  49. 49.
    Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, et al. Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39:199–205. doi: 10.1086/421944.PubMedGoogle Scholar
  50. 50.
    Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, et al. Multicenter clinical evaluation of the (1 → 3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41:654–9. doi: 10.1086/432470.PubMedGoogle Scholar
  51. 51.
    Perlin DS. Antifungal drug resistance: do molecular methods provide a way forward? Curr Opin Infect Dis. 2009;22:568–73. doi: 10.1097/QCO.0b013e3283321ce5.PubMedCentralPubMedGoogle Scholar
  52. 52.
    Kourkoumpetis TK, Fuchs BB, Coleman JJ, Desalermos A, Mylonakis E. Polymerase chain reaction-based assays for the diagnosis of invasive fungal infections. Clin Infect Dis. 2012;54:1322–31. doi: 10.1093/cid/cis132.PubMedCentralPubMedGoogle Scholar
  53. 53.
    Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2011;49:665–70. doi: 10.1128/JCM.01602-10.PubMedCentralPubMedGoogle Scholar
  54. 54.
    Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med. 2009;35:1526–31. doi: 10.1007/s00134-009-1482-8.PubMedGoogle Scholar
  55. 55.
    Gadea I, Cuenca-Estrella M, Martín E, Pemán J, Pontón J, Rodríguez-Tudela JL. Microbiological procedures for diagnosing mycoses and for antifungal susceptibility testing. Enferm Infecc Microbiol Clin. 2007;25:336–40; 13102270 [pii].PubMedGoogle Scholar
  56. 56.
    Richardson M, Ellis M. Clinical and laboratory diagnosis. Hosp Med. 2000;61:610–4.PubMedGoogle Scholar
  57. 57.
    Ruhnke M, Rickerts V, Cornely OA, Buchheidt D, Glöckner A, Heinz W, et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses. 2011;54:279–310. doi: 10.1111/j.1439-0507.2011.02040.x.PubMedGoogle Scholar
  58. 58.
    Clinical and Laboratory Standards Institute (CLSI). Principles and procedures for blood cultures; Approved guideline. CLSI document M47-A. Wayne, PA: CLSI; 2007.Google Scholar
  59. 59.
    Lee A, Mirrett S, Reller LB, Weinstein MP. Detection of bloodstream infections in adults: how many blood cultures are needed? J Clin Microbiol. 2007;45:3546–8. doi: 10.1128/JCM.01555-07.PubMedCentralPubMedGoogle Scholar
  60. 60.
    Washington JA 2nd. Blood cultures: principles and techniques. Mayo Clin Proc. 1975;50:91–8.PubMedGoogle Scholar
  61. 61.
    Cockerill FR 3rd, Wilson JW, Vetter EA, Goodman KM, Torgerson CA, Harmsen WS, et al. Optimal testing parameters for blood cultures. Clin Infect Dis. 2004;38:1724–30. doi: 10.1086/421087.PubMedGoogle Scholar
  62. 62.
    Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:1–45. doi: 10.1086/599376.PubMedGoogle Scholar
  63. 63.
    Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. Beta-d-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52:750–70. doi: 10.1093/cid/ciq206.PubMedGoogle Scholar
  64. 64.
    Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the (1 → 3)-beta-d-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2008;46:1009–13. doi: 10.1128/JCM.02091-07.PubMedCentralPubMedGoogle Scholar
  65. 65.
    Del Bono V, Delfino E, Furfaro E, Mikulska M, Nicco E, Bruzzi P, et al. Clinical performance of the (1,3)-beta-d-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. Clin Vaccine Immunol. 2011;18:2113–7. doi: 10.1128/CVI.05408-11.PubMedCentralPubMedGoogle Scholar
  66. 66.
    Eggimann P, Marchetti O. Is (1 → 3)-beta-d-glucan the missing link from bedside assessment to pre-emptive therapy of invasive candidiasis? Crit Care. 2011;15:1017. doi: 10.1186/cc10544.PubMedCentralPubMedGoogle Scholar
  67. 67.
    Presterl E, Parschalk B, Bauer E, Lassnigg A, Hajdu S, Graninger W. Invasive fungal infections and (1,3)-beta-d-glucan serum concentrations in long-term intensive care patients. Int J Infect Dis. 2009;13:707–12. doi: 10.1016/j.ijid.2008.10.013.PubMedGoogle Scholar
  68. 68.
    Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol. 2003;10:882–5.PubMedCentralPubMedGoogle Scholar
  69. 69.
    Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1 → 3)-beta-d-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2005;43:5957–62. doi: 10.1128/JCM.43.12.5957-5962.2005.PubMedCentralPubMedGoogle Scholar
  70. 70.
    Takesue Y, Kakehashi M, Ohge H, Imamura Y, Murakami Y, Sasaki M, et al. Combined assessment of beta-d-glucan and degree of candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg. 2004;28:625–30. doi: 10.1007/s00268-004-7302-y.PubMedGoogle Scholar
  71. 71.
    Mohr JF, Sims C, Paetznick V, Rodriguez J, Finkelman MA, Rex JH, et al. Prospective survey of (1 → 3)-beta-d-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol. 2011;49:58–61. doi: 10.1128/JCM.01240-10.PubMedCentralPubMedGoogle Scholar
  72. 72.
    Koo S, Bryar JM, Page JH, Baden LR, Marty FM. Diagnostic performance of the (1 → 3)-beta-d-glucan assay for invasive fungal disease. Clin Infect Dis. 2009;49:1650–9. doi: 10.1086/647942.PubMedGoogle Scholar
  73. 73.
    Acosta J, Catalan M, Del Palacio-Pérez-Medel A, Montejo JC, De-La-Cruz-Bértolo J, Moragues MD, et al. Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1,3)-beta-d-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease. Eur J Clin Microbiol Infect Dis. 2011;31:721–31. doi: 10.1007/s10096-011-1365-0.PubMedGoogle Scholar
  74. 74.
    Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M, et al. beta-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54:633–43. doi: 10.1093/cid/cir897.PubMedGoogle Scholar
  75. 75.
    Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, et al. Performance of Candida real-time polymerase chain reaction, beta-d-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012;54:1240–8. doi: 10.1093/cid/cis200.PubMedGoogle Scholar
  76. 76.
    Mokaddas E, Khan ZU, Ahmad S, Nampoory MR, Burhamah M. Value of (1–3)-beta-d-glucan, Candida mannan and Candida DNA detection in the diagnosis of candidaemia. Clin Microbiol Infect. 2011;17:1549–53. doi: 10.1111/j.1469-0691.2011.03608.x.PubMedGoogle Scholar
  77. 77.
    Prella M, Bille J, Pugnale M, Duvoisin B, Cavassini M, Calandra T, et al. Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis. 2005;51:95–101. doi: 10.1016/j.diagmicrobio.2004.08.015.PubMedGoogle Scholar
  78. 78.
    Sendid B, Poirot JL, Tabouret M, Bonnin A, Caillot D, Camus D, et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol. 2002;51:433–42.PubMedGoogle Scholar
  79. 79.
    Nihtinen A, Anttila VJ, Richardson M, Ruutu T, Juvonen E, Meri T, et al. Factors influencing the performance level of Candida mannan antigen testing in allogeneic stem cell transplant recipients not receiving fluconazole prophylaxis. Transpl Infect Dis. 2011;13:266–72. doi: 10.1111/j.1399-3062.2010.00593.x.PubMedGoogle Scholar
  80. 80.
    Maaroufi Y, Heymans C, De Bruyne JM, Duchateau V, Rodriguez-Villalobos H, Aoun M, et al. Rapid detection of Candida albicans in clinical blood samples by using a TaqMan-based PCR assay. J Clin Microbiol. 2003;41:3293–8.PubMedCentralPubMedGoogle Scholar
  81. 81.
    Moreira-Oliveira MS, Mikami Y, Miyaji M, Imai T, Schreiber AZ, Moretti ML. Diagnosis of candidemia by polymerase chain reaction and blood culture: prospective study in a high-risk population and identification of variables associated with development of candidemia. Eur J Clin Microbiol Infect Dis. 2005;24:721–6. doi: 10.1007/s10096-005-0041-7.PubMedGoogle Scholar
  82. 82.
    Einsele H, Loeffler J. Contribution of new diagnostic approaches to antifungal treatment plans in high-risk haematology patients. Clin Microbiol Infect. 2008;14:37–45. doi: 10.1111/j.1469-0691.2008.01980.x.PubMedGoogle Scholar
  83. 83.
    Falcone M, Barzaghi N, Carosi G, Grossi P, Minoli L, Ravasio V, et al. Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore). 2009;88:160–8. doi: 10.1097/MD.0b013e3181a693f8.Google Scholar
  84. 84.
    Shoham S, Shaffer R, Sweet L, Cooke R, Donegan N, Boyce S. Candidemia in patients with ventricular assist devices. Clin Infect Dis. 2007;44:e9–12. doi: 10.1086/509640.PubMedGoogle Scholar
  85. 85.
    Pierrotti LC, Baddour LM. Fungal endocarditis, 1995–2000. Chest. 2002;122:302–10.PubMedGoogle Scholar
  86. 86.
    Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54:1110–22. doi: 10.1093/cid/cis021.PubMedGoogle Scholar
  87. 87.
    Rodríguez-Adrián LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. Medicine (Baltimore). 2003;82:187–202. doi: 10.1097/ Scholar
  88. 88.
    Parke DW 2nd, Jones DB, Gentry LO. Endogenous endophthalmitis among patients with candidemia. Ophthalmology. 1982;89:789–96.PubMedGoogle Scholar
  89. 89.
    Oude Lashof AM, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, et al. Ocular manifestations of candidemia. Clin Infect Dis. 2011;53:262–8. doi: 10.1093/cid/cir355.PubMedGoogle Scholar
  90. 90.
    Nagao M, Saito T, Doi S, Hotta G, Yamamoto M, Matsumura Y, et al. Clinical characteristics and risk factors of ocular candidiasis. Diagn Microbiol Infect Dis. 2012;73:149–52. doi: 10.1016/j.diagmicrobio.2012.03.006.PubMedGoogle Scholar
  91. 91.
    Koo S, Baden LR, Marty FM. Post-diagnostic kinetics of the (1 → 3)-beta-d-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia. Clin Microbiol Infect. 2012;18:E122–7. doi: 10.1111/j.1469-0691.2012.03777.x.PubMedCentralPubMedGoogle Scholar
  92. 92.
    Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-beta-d-Glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis. 2012;55:521–6. doi: 10.1093/cid/cis456.PubMedGoogle Scholar
  93. 93.
    Pazos C, Moragues MD, Quindós G, Pontón J, del Palacio A. Diagnostic potential of (1,3)-beta-d-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev Iberoam Micol. 2006;23:209–15 (pii:200623209).PubMedGoogle Scholar
  94. 94.
    Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med. 1999;27:1066–72.PubMedGoogle Scholar
  95. 95.
    Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med. 2002;28:1708–17. doi: 10.1007/s00134-002-1540-y.PubMedGoogle Scholar
  96. 96.
    Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med. 2005;33:1928–35; quiz 36 (pii:00003246-200509000-00005).PubMedGoogle Scholar
  97. 97.
    Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3:685–702 (pii:S1473309903008016).PubMedGoogle Scholar
  98. 98.
    Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis. 2001;32:1191–200. doi: 10.1086/319763.PubMedGoogle Scholar
  99. 99.
    McKinnon PS, Goff DA, Kern JW, Devlin JW, Barletta JF, Sierawski SJ, et al. Temporal assessment of Candida risk factors in the surgical intensive care unit. Arch Surg. 2001;136:1401–8; discussion 9 (pii:soa1025).PubMedGoogle Scholar
  100. 100.
    Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis. 2001;33:177–86. doi: 10.1086/321811.PubMedGoogle Scholar
  101. 101.
    Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother. 2006;57:628–38. doi: 10.1093/jac/dki491.PubMedGoogle Scholar
  102. 102.
    Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg. 2001;233:542–8.PubMedCentralPubMedGoogle Scholar
  103. 103.
    Faiz S, Neale B, Rios E, Campos T, Parsley E, Patel B, et al. Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit. Eur J Clin Microbiol Infect Dis. 2009;28:689–92. doi: 10.1007/s10096-008-0666-4.PubMedGoogle Scholar
  104. 104.
    Vardakas KZ, Samonis G, Michalopoulos A, Soteriades ES, Falagas ME. Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit Care Med. 2006;34:1216–24. doi: 10.1097/01.CCM.0000208357.05675.C3.PubMedGoogle Scholar
  105. 105.
    Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials. 2009;10:37. doi: 10.1186/1745-6215-10-37.PubMedCentralPubMedGoogle Scholar
  106. 106.
    Schuster MG, Edwards JE Jr, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med. 2008;149:83–90; 149/2/83 [pii].PubMedGoogle Scholar
  107. 107.
    Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother. 2007;60:613–8. doi: 10.1093/jac/dkm212.PubMedGoogle Scholar
  108. 108.
    Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009;136:1237–48. doi: 10.1378/chest.09-0087.PubMedGoogle Scholar
  109. 109.
    Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother. 2010;54:184–90. doi: 10.1128/AAC.00945-09.PubMedCentralPubMedGoogle Scholar
  110. 110.
    Montravers P, Dupont H, Gauzit R, Veber B, Auboyer C, Blin P, et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med. 2006;34:646–52. doi: 10.1097/01.CCM.0000201889.39443.D2.PubMedGoogle Scholar
  111. 111.
    Montravers P, Mira JP, Gangneux JP, Leroy O, Lortholary O. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect. 2011;17:1061–7. doi: 10.1111/j.1469-0691.2010.03360.x.PubMedGoogle Scholar
  112. 112.
    Karthaus M, Rüping MJ, Cornely OA, Steinbach A, Groll AH, Lass-Flörl C, et al. Current issues in the clinical management of invasive candida infections—the AGIHO, DMykG, ÖGMM and PEG web-based survey and expert consensus conference 2009. Mycoses. 2011;54:e546–56. doi: 10.1111/j.1439-0507.2010.01988.x.PubMedGoogle Scholar
  113. 113.
    Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011;66:2146–51. doi: 10.1093/jac/dkr244.PubMedGoogle Scholar
  114. 114.
    Kourkoumpetis TK, Velmahos GC, Ziakas PD, Tampakakis E, Manolakaki D, Coleman JJ, et al. The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients. Mycopathologia. 2011;171:85–91. doi: 10.1007/s11046-010-9369-3.PubMedGoogle Scholar
  115. 115.
    Shah DN, Yau R, Lasco TM, Weston J, Salazar M, Palmer HR, et al. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother. 2012;56:3239–43. doi: 10.1128/AAC.00019-12.PubMedCentralPubMedGoogle Scholar
  116. 116.
    Ha YE, Peck KR, Joo EJ, Kim SW, Jung SI, Chang HH, et al. Impact of first-line antifungal agents on the outcomes and costs of candidemia. Antimicrob Agents Chemother. 2012;56:3950–6. doi: 10.1128/AAC.06258-11.PubMedCentralPubMedGoogle Scholar
  117. 117.
    Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother. 2012;56:2518–23. doi: 10.1128/AAC.05947-11.PubMedCentralPubMedGoogle Scholar
  118. 118.
    Tortorano AM, Prigitano A, Dho G, Grancini A, Passera M. Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units. J Med Microbiol. 2012;61:389–93. doi: 10.1099/jmm.0.037895-0.PubMedGoogle Scholar
  119. 119.
    van der Voort PH, Boerma EC, Yska JP. Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis. J Antimicrob Chemother. 2007;59:952–6. doi: 10.1093/jac/dkm074.PubMedGoogle Scholar
  120. 120.
    Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020–9. doi: 10.1056/NEJMoa021585.PubMedGoogle Scholar
  121. 121.
    Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369:1519–27. doi: 10.1016/S0140-6736(07)60605-9.PubMedGoogle Scholar
  122. 122.
    Reboli AC, Shorr AF, Rotstein C, Pappas PG, Kett DH, Schlamm HT, et al. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis. 2011;11:261. doi: 10.1186/1471-2334-11-261.PubMedCentralPubMedGoogle Scholar
  123. 123.
    Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883–93. doi: 10.1086/520980.PubMedGoogle Scholar
  124. 124.
    Glöckner A. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin: review of the literature. Eur J Med Res. 2011;16:167–79.PubMedCentralPubMedGoogle Scholar
  125. 125.
    Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356:2472–82. doi: 10.1056/NEJMoa066906.PubMedGoogle Scholar
  126. 126.
    Rodriguez D, Park BJ, Almirante B, Cuenca-Estrella M, Planes AM, Mensa J, et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect. 2007;13:788–93. doi: 10.1111/j.1469-0691.2007.01758.x.PubMedGoogle Scholar
  127. 127.
    Gafter-Gvili A, Vidal L, Goldberg E, Leibovici L, Paul M. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc. 2008;83:1011–21. doi: 10.4065/83.9.1011.PubMedGoogle Scholar
  128. 128.
    Ruhnke M, Paiva JA, Meersseman W, Pachl J, Grigoras I, Sganga G, et al. Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. Clin Microbiol Infect. 2012;18:680–7. doi: 10.1111/j.1469-0691.2012.03784.x.PubMedCentralPubMedGoogle Scholar
  129. 129.
    Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008–2009. Antimicrob Agents Chemother. 2010;55:561–6. doi: 10.1128/AAC.01079-10.PubMedCentralPubMedGoogle Scholar
  130. 130.
    Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009). Int J Antimicrob Agents. 2011;38:65–9. doi: 10.1016/j.ijantimicag.2011.02.016.PubMedGoogle Scholar
  131. 131.
    Cantón E, Pemán J, Quindós G, Eraso E, Miranda-Zapico I, Álvarez M, et al. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother. 2011;55:5590–6. doi: 10.1128/AAC.00466-11.PubMedCentralPubMedGoogle Scholar
  132. 132.
    Blanchard E, Lortholary O, Boukris-Sitbon K, Desnos-Ollivier M, Dromer F, Guillemot D. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case–control study in Paris, France. Antimicrob Agents Chemother. 2011;55:5358–61. doi: 10.1128/AAC.00690-11.PubMedCentralPubMedGoogle Scholar
  133. 133.
    Spreghini E, Orlando F, Tavanti A, Senesi S, Giannini D, Manso E, et al. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. J Antimicrob Chemother. 2012;67:2195–202. doi: 10.1093/jac/dks180.PubMedGoogle Scholar
  134. 134.
    Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis. 2009;48:1676–84. doi: 10.1086/598933.PubMedGoogle Scholar
  135. 135.
    Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care. 2009;13:R159. doi: 10.1186/cc8117.PubMedCentralPubMedGoogle Scholar
  136. 136.
    Mistro S, Maciel Ide M, de Menezes RG, Maia ZP, Schooley RT, Badaró R. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis. 2012;54:1774–7. doi: 10.1093/cid/cis290.PubMedGoogle Scholar
  137. 137.
    Ullmann AJ, Sanz MA, Tramarin A, Barnes RA, Wu W, Gerlach BA, et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis. 2006;43:e29–38. doi: 10.1086/505969.PubMedGoogle Scholar
  138. 138.
    Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int. 2001;60:1452–9. doi: 10.1046/j.1523-1755.2001.00948.x.PubMedGoogle Scholar
  139. 139.
    Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis. 1996;23:964–72.PubMedGoogle Scholar
  140. 140.
    Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994;331:1325–30. doi: 10.1056/NEJM199411173312001.PubMedGoogle Scholar
  141. 141.
    Phillips P, Shafran S, Garber G, Rotstein C, Smaill F, Fong I, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis. 1997;16:337–45.PubMedGoogle Scholar
  142. 142.
    Oude Lashof AM, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schlamm HT, et al. Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia. Antimicrob Agents Chemother. 2012;56:3133–7. doi: 10.1128/AAC.05841-11.PubMedCentralPubMedGoogle Scholar
  143. 143.
    Mikulska M, Novelli A, Aversa F, Cesaro S, de Rosa FG, Girmenia C, et al. Voriconazole in clinical practice. J Chemother. 2012;24:311–27. doi: 10.1179/1973947812Y.0000000051.PubMedGoogle Scholar
  144. 144.
    Tuil O, Cohen Y. Itraconazole IV solution in the treatment of candidemia in non-neutropenic patients. Crit Care. 2003;7:P131.PubMedCentralGoogle Scholar
  145. 145.
    Kullberg BJ, Verweij PE, Akova M, Arendrup MC, Bille J, Calandra T, et al. European expert opinion on the management of invasive candidiasis in adults. Clin Microbiol Infect. 2011;17:1–12. doi: 10.1111/j.1469-0691.2011.03615.x.PubMedGoogle Scholar
  146. 146.
    Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect. 2008;56:126–9. doi: 10.1016/j.jinf.2007.10.014.PubMedGoogle Scholar
  147. 147.
    Lefort A, Chartier L, Sendid B, Wolff M, Mainardi JL, Podglajen I, et al. Diagnosis, management and outcome of Candida endocarditis. Clin Microbiol Infect. 2012;18:E99–109. doi: 10.1111/j.1469-0691.2012.03764.x.PubMedGoogle Scholar
  148. 148.
    Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis. 2011;52:648–53. doi: 10.1093/cid/ciq204.PubMedGoogle Scholar
  149. 149.
    Hariprasad SM, Mieler WF, Holz ER, Gao H, Kim JE, Chi J, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol. 2004;122:42–7. doi: 10.1001/archopht.122.1.42.PubMedGoogle Scholar
  150. 150.
    Kujath P, Lerch K, Kochendörfer P, Boos C. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection. 1993;21:376–82.PubMedGoogle Scholar
  151. 151.
    Shah CP, McKey J, Spirn MJ, Maguire J. Ocular candidiasis: a review. Br J Ophthalmol. 2008;92:466–8. doi: 10.1136/bjo.2007.133405.PubMedGoogle Scholar
  152. 152.
    Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005;366:1435–42. doi: 10.1016/S0140-6736(05)67490-9.PubMedGoogle Scholar
  153. 153.
    Ozdemir H, Karbuz A, Ciftçi E, Dinçaslan HU, Ince E, Aysev D, et al. Successful treatment of central venous catheter infection due to Candida lipolytica by caspofungin-lock therapy. Mycoses. 2011;54:e647–9. doi: 10.1111/j.1439-0507.2010.01964.x.PubMedGoogle Scholar
  154. 154.
    Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood. 2005;106:2641–5. doi: 10.1182/blood-2005-02-0733.PubMedGoogle Scholar
  155. 155.
    Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004;64:1997–2020 (pii:64181).PubMedGoogle Scholar
  156. 156.
    Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003;37:728–32. doi: 10.1086/377131.PubMedGoogle Scholar
  157. 157.
    Black KE, Baden LR. Fungal infections of the CNS: treatment strategies for the immunocompromised patient. CNS Drugs. 2007;21:293–318 (pii:2144).PubMedGoogle Scholar
  158. 158.
    Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. 1979;301:126–31. doi: 10.1056/NEJM197907193010303.PubMedGoogle Scholar
  159. 159.
    Fan-Havard P, O’Donovan C, Smith SM, Oh J, Bamberger M, Eng RH. Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Clin Infect Dis. 1995;21:960–5.PubMedGoogle Scholar
  160. 160.
    Fisher JF, Sobel JD, Kauffman CA, Newman CA. Candida urinary tract infections—treatment. Clin Infect Dis. 2011;52:S457–66. doi: 10.1093/cid/cir112.PubMedGoogle Scholar
  161. 161.
    Khazim RM, Debnath UK, Fares Y. Candida albicans osteomyelitis of the spine: progressive clinical and radiological features and surgical management in three cases. Eur Spine J. 2006;15:1404–10. doi: 10.1007/s00586-005-0038-z.PubMedCentralPubMedGoogle Scholar
  162. 162.
    Schilling A, Seibold M, Mansmann V, Gleissner B. Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/posaconazole therapy. Med Mycol. 2008;46:79–83. doi: 10.1080/13693780701552996.PubMedGoogle Scholar
  163. 163.
    Kaldau NC, Brorson S, Jensen PE, Schultz C, Arpi M. Bilateral polymicrobial osteomyelitis with Candida tropicalis and Candida krusei: a case report and an updated literature review. Int J Infect Dis. 2012;16:e16–22. doi: 10.1016/j.ijid.2011.10.001.PubMedGoogle Scholar
  164. 164.
    Slenker AK, Keith SW, Horn DL. Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature. Diagn Microbiol Infect Dis. 2012;73:89–93. doi: 10.1016/j.diagmicrobio.2012.02.004.PubMedGoogle Scholar
  165. 165.
    Micafungin lock therapy to clear fungemia while attempting to preserve central venous catheters. Trial code: NCT00809887.
  166. 166.
    McMullan R, Metwally L, Coyle PV, Hedderwick S, McCloskey B, O’Neill HJ, et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis. 2008;46:890–6. doi: 10.1086/528690.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • L. Scudeller
    • 1
    Email author
  • C. Viscoli
    • 2
  • F. Menichetti
    • 3
  • V. del Bono
    • 2
  • F. Cristini
    • 4
  • C. Tascini
    • 3
  • M. Bassetti
    • 5
  • P. Viale
    • 4
  1. 1.Clinical Epidemiology Unit, Scientific DirectionIRCCS Policlinico San Matteo FoundationPaviaItaly
  2. 2.Clinic of Infectious Diseases, IRCCS San Martino-ISTUniversity of GenuaGenoaItaly
  3. 3.Infectious Disease DepartmentCisanello HospitalPisaItaly
  4. 4.Infectious Diseases Unit, Teaching Hospital Policlinico S. Orsola-Malpighi Alma Mater StudiorumUniversity of BolognaBolognaItaly
  5. 5.Infectious Diseases DivisionSanta Maria della Misericordia University HospitalUdineItaly

Personalised recommendations